Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LIMK1 | P53667 | 4/20 | 0.72 |
| ▸ | NPC1 | O15118 | 6/20 | 0.50 |
| ▸ | RAB9A | P51151 | 5/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.46 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.46 |
| ▸ | MAPT | P10636 | 5/20 | 0.45 |
| ▸ | HTT | P42858 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.43 |
| ▸ | HPGD | P15428 | 3/20 | 0.43 |
| ▸ | USP2 | O75604 | 1/20 | 0.43 |
| ▸ | TLR9 | Q9NR96 | 2/20 | 0.43 |
| ▸ | CLK1 | P49759 | 2/20 | 0.43 |
| ▸ | MEN1 | O00255 | 2/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.43 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.43 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.43 |
| ▸ | ATM | Q13315 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4901470 | 0.84 | LIMK1 (1.00) | LIMK1NPC1RAB9AKDM4EHSD17B10 | |
| SCHEMBL4902497 | 0.82 | MEN1 (0.53) | LIMK1NPC1RAB9AKDM4ESMN1; SMN2 | |
| SCHEMBL4899997 | 0.79 | MAPT (0.50) | LIMK1KDM4ESMN1; SMN2HSD17B10MAPT | |
| SCHEMBL4903044 | 0.77 | MAPT (0.70) | LIMK1NPC1RAB9AKDM4ESMN1; SMN2 | |
| SCHEMBL4893147 | 0.74 | MAPT (0.66) | LIMK1KDM4ESMN1; SMN2HSD17B10MAPT | |
| SCHEMBL19805093 | 0.73 | LIMK1 (0.53) | LIMK1NPC1RAB9AKDM4ESMN1; SMN2 | |
| SCHEMBL13040779 | 0.73 | NLRP3 (0.61) | LIMK1KDM4ESMN1; SMN2HSD17B10ALDH1A1 | |
| SCHEMBL19805090 | 0.71 | NPC1 (0.61) | LIMK1NPC1RAB9AKDM4ESMN1; SMN2 | |
| SCHEMBL4901029 | 0.71 | HPGD (0.60) | KDM4ESMN1; SMN2HSD17B10MAPTALDH1A1 | |
| SCHEMBL4902570 | 0.70 | LIMK1 (0.74) | LIMK1NPC1RAB9AKDM4EHSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080008720-A1 | Substituted Tricyclic Heterocycles and their Uses | CYWIN CHARLES L | 2008-01-10 | — | — | US | disclosed |
| US-7291733-B2 | Substituted tricyclic heterocycles and their uses | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 2007-11-06 | — | — | US | disclosed |
| EP-1673374-A2 | SUBSTITUTED TRICYCLIC HETEROCYCLES AND THEIR USES | BOEHRINGER INGELHEIM PHARMACEUTICALS INC. (US) | 2006-06-28 | — | — | EP | disclosed |
| US-20050101601-A1 | Substituted tricyclic heterocycles and their uses | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 2005-05-12 | — | — | US | disclosed |
| WO-2005035537-A2 | SUBSTITUTED TRICYCLIC HETEROCYCLES AND THEIR USES | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 2005-04-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050101601-A1 | Substituted tricyclic heterocycles and their uses | LTC4S, NQO1, CBR3 | LIMK1 4013/4885NPC1 2575/4885RAB9A 3123/4885 |
| US-20080008720-A1 | Substituted Tricyclic Heterocycles and their Uses | LTC4S, NQO1, CBR3 | LIMK1 4013/4885NPC1 2575/4885RAB9A 3123/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.